Physician profile
Alexis Rod
NPI 1083867832
$1,208.49
in general payments reported to CMS, 2019-2025
24 companies · $42.32 in 2025
The $42.32 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2022: $436 · 2023: $315 · 2024: $115 · 2025: $42.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $243.17 | 2021-2023 | |
| Novo Nordisk INC | $155.12 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $143.50 | 2021-2023 | Mounjaro |
| Abbott Laboratories | $88.83 | 2021-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.47 | 2021-2023 | Xifaxan |
| Medtronic, INC. | $56.72 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $48.05 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.70 | 2021 | |
| Pfizer INC. | $34.23 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $33.89 | 2021-2022 | |
| Axsome Therapeutics, INC. | $33.15 | 2023 | Auvelity |
| Dexcom, INC. | $32.17 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $28.91 | 2021-2022 | |
| Exact Sciences Corporation | $24.45 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $21.49 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $19.39 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Esperion Therapeutics, INC. | $19.27 | 2021 | |
| Biogen, INC. | $18.12 | 2021 | |
| Heartflow, INC. | $18.05 | 2024 | |
| Inspire Medical Systems, INC. | $17.87 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $15.33 | 2022 | |
| Dynavax Technologies Corporation | $13.79 | 2023 | Heplisav-B |
| Glaxosmithkline, LLC. | $13.62 | 2023 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $13.20 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Rod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.